Clinical trials: Stage II Ovarian Cancer
Pancreatic Cancer, Ovarian Cancer
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
To find the recommended dose of TROP2- CAR-NK given intraperitoneally (directly into the abdominal cavity) to patients with highgrade serous ovarian cancer that has not responded to previous treatment or is resistant to treatment.
- Conditions
- Pancreatic Cancer, Ovarian Cancer, Adenocarcinoma
- Trial name
- NCT05922930
- Testing
- TROP2-CAR-NK, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Stromal Sarcoma, Adenosarcoma of Uterus
FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study
This phase 2 clinical trial aims to evaluate the efficacy of Fulvestrant, an ER-antagonist, in women with estrogen receptor positive (ER+) low-grade gynecological cancers.
- Conditions
- Endometrial Stromal Sarcoma, Adenosarcoma of Uterus, Leiomyosarcoma Uterus, Endometrial Cancer
- Trial name
- FUCHSia (NCT03926936)
- Testing
- Fulvestrant
- Where
- 14 sites in Belgium, Netherlands
- Volunteers
- 17 people
- Sponsor
- Frederic Amant
Cancer
Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Trial name
- NCT00003538
- Testing
- graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ovarian Cancer, Testicular Germ Cell Tumor
Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003518
- Testing
- gemcitabine hydrochloride, paclitaxel
- Where
- 19 sites in United States, South Africa
- Volunteers
- 44 people
- Sponsor
- Eastern Cooperative Oncology Group
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase II trial studies how well pemetrexed disodium and carboplatin work in treating patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01001910
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Pemetrexed Disodium
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Albert Einstein College of Medicine
Ovarian Neoplasm, Fallopian Tube Cancer
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
Background: Sorafenib and bevacizumab are anti-cancer drugs that work by targeting the blood vessels that allow tumors to grow. Using the two drugs together may more effectively block the formation of blood vessels that feed…
- Conditions
- Ovarian Neoplasm, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT00436215
- Testing
- Bevacizumab, BAY 43-9006
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)